A phase 3 study evaluating the safety and efficacy of a pediatric dose of mometasone furoate with and without formoterol for persistent asthma.
Administration, Inhalation
Adrenal Cortex Hormones
/ therapeutic use
Asthma
/ drug therapy
Bronchodilator Agents
/ administration & dosage
Child
Child, Preschool
Double-Blind Method
Drug Therapy, Combination
Female
Formoterol Fumarate
/ administration & dosage
Humans
Male
Metered Dose Inhalers
Mometasone Furoate
/ administration & dosage
Nebulizers and Vaporizers
Spirometry
Treatment Outcome
children
formoterol
mometasone furoate
persistent asthma
Journal
Pediatric pulmonology
ISSN: 1099-0496
Titre abrégé: Pediatr Pulmonol
Pays: United States
ID NLM: 8510590
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
12
09
2019
accepted:
15
01
2020
pubmed:
6
2
2020
medline:
11
11
2020
entrez:
6
2
2020
Statut:
ppublish
Résumé
Asthma affects over 6 million children in the United States alone. This study investigated the efficacy and long-term safety of mometasone furoate-formoterol (MF/F) and MF monotherapy in children with asthma. This phase 3, multicenter, randomized controlled trial evaluated metered-dose inhaler twice daily (BID) dosing with MF/F 100/10 µg or MF 100 µg in children, aged 5 to 11 years, with a history of asthma for greater than or equal to 6 months and confirmed bronchodilator reversibility, who were adequately controlled on inhaled corticosteroid/long-acting beta-agonist combination therapy for greater than or equal to 4 weeks. After a 2-week run-in on MF 100 µg BID, eligible patients received 24 weeks of double-blind treatment and were followed for safety up to 26 weeks. The primary efficacy endpoint was the change from baseline in AM postdose 60-minute AUC %predicted FEV1% across 12 weeks of treatment. A total of 181 participants received at least one dose of MF/F (n = 91) or MF (n = 90). MF/F was superior to MF across the 12-week evaluation period, with a treatment advantage of 5.21 percentage points (P < .001). Superior onset of action with MF/F over MF was achieved as early as 5 minutes postdose on day 1. Overall, approximately 50% of participants experienced one or more treatment-emergent adverse events, with fewer occurring in the MF/F group. In children 5 to 11 years of age with persistent asthma, the addition of F to MF was well tolerated and provided significant, rapid, and sustained improvement in lung function compared with MF alone.
Substances chimiques
Adrenal Cortex Hormones
0
Bronchodilator Agents
0
Mometasone Furoate
04201GDN4R
Formoterol Fumarate
W34SHF8J2K
Types de publication
Clinical Trial, Phase III
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
882-889Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Weinstein CL, Gates D, Zhang X, et al. P211 Efficacy and safety of mometasone furoate/formoterol compared with mometasone furoate in children with persistent asthma. Ann Allergy Asthma Immunol. 2019;123(suppl):S35.
Centers for Disease Control and Prevention. Most recent national asthma data. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. Accessed May 1, 2019.
Global Initiative for Asthma. https://ginasthma.org/. Accessed January 18, 2019.
US prescribing information for ASMANEX® HFA (mometasone furoate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/205641s007s008lbl.pdf. Accessed May 1, 2019.
US prescribing information for ASMANEX® TWISTHALER® 110 mcg, 220 mcg (mometasone furoate inhalation powder) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021067s026,s028lbl.pdf. Accessed May 1, 2019.
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1:356-363.
US prescribing information for FORADIL® (formoterol fumarate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021592s003lbl.pdf. Accessed May 1, 2019.
US prescribing information for DULERA® (mometasone furoate and formoterol fumarate dihydrate). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022518s023s024lbl.pdf. Accessed May 1, 2019.
Weinstein C, Staudinger H, Scott I, Amar NJ, Laforce C. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir Med. 2011;105:979-988.
LaForce C, Weinstein C, Nathan RA, Weinstein SF, Staudinger H, Meltzer EO. Patient satisfaction with a pressurized metered-dose inhaler with an integrated dose counter containing a fixed-dose mometasone furoate/formoterol combination. J Asthma. 2011;48:625-631.
Berger WE, Bensch GW, Weinstein SF, et al. Bronchodilation with mometasone furoate/formoterol fumarate administered by metered-dose inhaler with and without a spacer in children with persistent asthma. Pediatr Pulmonol. 2014;49:441-450.
Amar NJ, Shekar T, Varnell TA, Mehta A, Philip G. Mometasone furoate (MF) improves lung function in pediatric asthma: a double-blind, randomized controlled dose-ranging trial of MF metered-dose inhaler. Pediatr Pulmonol. 2017;52:310-318. https://doi.org/10.1002/ppul.23563. Erratum: Pediatr Pulmonol. 2019;54:655-656. https://doi.org/10.1002/ppul.24291
Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-338.
Polgar G, Promadhat V. Pulmonary Function Testing in Children: Techniques and Standards. Philadelphia, PA: Saunders; 1971.
Ratitch B, O'Kelly M, Tosiello R. Missing data in clinical trials: from clinical assumptions to statistical analysis using pattern mixture models. Pharm Stat. 2013;12:337-347.
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4:213-226.
Skoner DP, Meltzer EO, Milgrom H, Stryszak P, Teper A, Staudinger H. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. J Asthma. 2011;48:848-859.
Busse WW, Bateman ED, Caplan AL, et al. Combined analysis of asthma safety trials of long-acting beta(2)-agonists. N Engl J Med. 2018;378:2497-2505.
Stempel DA, Szefler SJ, Pedersen S, et al. Safety of adding salmeterol to fluticasone propionate in children with asthma. N Engl J Med. 2016;375:840-849.